Vemurafenib for <i>BRAF</i> V600–Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis

L. Diamond, Eli; Subbiah, Vivek; Craig Lockhart, A.; Blay, Jean‐Yves; Puzanov, Igor; Chau, Ian; Raje, Noopur; Wolf, Jürgen; P. Erinjeri, Joseph; Torrisi, Jean; E. Lacouture, Mario; Élez, Elena; Martínez-Valle, Ferran; H. Durham, Benjamin; E. Arcila, Maria; A. Ulaner, Gary; Abdel‐Wahab, Omar; Pitcher, Bethany; Makrutzki, Martina; Riehl, Todd; Baselga, José; M. Hyman, David

doi:10.1001/jamaoncol.2017.5029

Public

Vemurafenib for BRAF V600–Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis

Published in JAMA Oncology • Nov 29, 2017

Authors:

Eli L. Diamond

Vivek Subbiah

A. Craig Lockhart

Abstract

IMPORTANCE: The histiocytic neoplasms Erdheim-Chester disease (ECD) and Langerhans cell histiocytosis (LCH) are highly enriched for BRAF V600 mutations and have been previously shown to be responsive to treatment with vemurafenib, an inhibitor of the BRAF V600 kinase. However, the long-term efficacy...

Subject

Vemurafenib

Medicine

V600E

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!